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Extra-articular manifestations and 
comorbidities in spondyloarthritis
Introduction
Spondyloarthritis (SpA) is a group of chronic 
auto-inflammatory diseases characterised by 
peripheral and/or axial inflammation. Ankylosing 
spondylitis (AS) is characterised by axial inflam-
mation and is the archetypal and most common 
type of spondyloarthritis, with regional preva-
lence ranging from 0.02–0.35%.1 Psoriatic 
arthritis (PsA), on the other hand, is character-
ised predominantly by peripheral inflammation. 
Prevalence of PsA remains largely unknown due 
to lack of data from some regions and due to dif-
fering classifications, but current estimates are 
about 0.02–0.25%.2 Though distinct, both 
diseases share common pathological features, 
with inflammation playing a crucial role. For 
instance, HLA-B27 gene polymorphisms are 
implicated in various spondyloarthritis.3 HLA-
B27 is associated with spinal involvement,4 which 
may explain its strong association with AS,5 where 
it accounts for about 30% of heritability of the 
illness.6 Similarly, dysregulation of interleukin 
17/23 pathway is implicated in the pathogenesis 
of both AS and PsA.7,8 Other implicated inflam-
matory cytokines include tumour necrosis factor 
alpha (TNF-α), IL-6 and IL-22.9,10 Such patho-
physiologic similarity is reflected in common clin-
ical features. For example, psychiatric symptoms/
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disorders, especially depression, are common in 
both AS and PsA, which may be linked with poten-
tial shared mechanisms such as inflammation.
Depression is a common and serious mental dis-
order that affects about 10–20% of the popula-
tion in the lifetime,11 with a quarter of these cases 
beginning before age 20 years.12 It is one of the 
leading contributors of disability-adjusted life-
years globally.13 Depressive symptoms can be 
broadly grouped as somatic or psychological. 
Somatic symptoms include fatigue, sleep distur-
bance, changes in appetite/weight, psychomotor 
agitation/retardation, and anhedonia (loss of 
pleasure). Psychological symptoms can include 
hopelessness, low self-esteem, excessive/inappro-
priate guilt and suicidality.14 Typically, depres-
sion has a relapsing remitting nature, with high 
recurrence rate; up to 50% after the first episode 
and up to 90% after the third episode.15–17 Similar 
to most chronic illnesses of adult life, depression 
is a multifactorial condition with contributions 
from both genetic and environmental factors. 
Recent genome-wide association studies have 
identified over 100 genetic variants associated with 
depression.18–20 These include genetic variants 
linked to specific brain regions such as the prefron-
tal cortex (SORCS3 on chromosome 10 and NEGR1 
on chromosome 1),19 and neuro-transmission/
signalling involving calcium (CACNA1E and 
CACNA2D1), dopamine (DRD2), and gluta-
mate (GRIK5 and GRM5).18,20 The majority of 
genes identified were in the extended major histo-
compatibility complex (MHC) region,20 a region 
that is essential for autoimmunity.21 The cumula-
tive effect of these variants on risk is relatively 
modest, with common single nucleotide polymor-
phisms (SNPs) contributing about 9% variation 
in depression liability.18 Notable environmental 
risk factors include stressful life events and early-
life adversity such as abuse/maltreatment.
Pathophysiologic explanation and pharmacother-
apy for depression is predicated on monoamine 
neurotransmitters, particularly serotonin. However, 
about a third of patients with depression do not 
respond to monoaminergic treatment such as 
selective serotonin reuptake inhibitors (SSRIs),22 
suggesting other mechanisms contribute to illness 
risk. Emerging evidence indicates a potentially 
causal role for inflammation in the pathogenesis of 
depression.23–25 Depression is often comorbid 
with physical illnesses, notably cardiovascular dis-
ease and auto-immune/auto-inflammatory condi-
tions such as arthritis.26 Inflammation could be a 
shared mechanism for depression and cardiovas-
cular and possibly other comorbid physical ill-
nesses such as type 2 diabetes.22,27,28
Depression is a clinically relevant issue for rheu-
matologists as depressive symptoms are present 
in over a third of patients with rheumatological 
conditions, including rheumatoid arthritis (RA), 
axial spondyloarthritis and PsA.29–31 Depression 
is associated with poor adherence to treatment for 
chronic physical illness.32 Persistent depressive 
symptoms have been reported to not only exacer-
bate disease activity and disability but also poten-
tially reduce treatment response.33,34 As a result, 
treating depression alone can improve rheumato-
logical outcomes.
In this review, we discuss the current literature 
regarding the burden of depression in spondyloar-
thritis using AS and PsA as examples. We discuss 
prevalence, incidence, risk factors and potential 
mechanisms for the higher risk of depression in 
patients with AS and PsA. We review the current 
guidance on the management of depression as rel-
evant to rheumatology clinicians.
Prevalence and incidence of depression in 
patients with AS or PsA
Depression is common in patients with rheuma-
tological conditions including SpA with evidence 
for a complex bi-directional relationship. For 
instance, depression may exacerbate disease 
activity in patients with AS or PsA, while disease 
severity and certain symptoms can contribute to 
low mood. A Swedish population-based study 
reported that individuals with rheumatological 
disease had a higher risk of psychiatric disorders 
than the general population, with incidence rates 
showing an increase of 48.2 men per 100,000, 
and 45 women per 100,000.35 Those with AS or 
systemic lupus erythematosus (SLE) had a higher 
risk of subsequent psychiatric disorder(s) com-
pared with patients with RA, while depression 
was the leading cause for psychiatric hospitalisa-
tion in patients with AS.35 However, this study 
examined severe psychiatric illness requiring hos-
pitalisation as the outcome, and so may not reflect 
the burden of less severe psychiatric morbidity. A 
more recent study of comorbidities in axial spon-
dyloarthritis (axSpA) used clinical information 
from clinical notes, and primary and secondary 
medical records to investigate a broader spectrum 
of comorbidities, not limited to hospitalisation or 
psychiatric illness. Depression was reported to be 
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one of the most common comorbidities in axSpA, 
present in about 15% of patients. Using hierar-
chical clustering of 38 conditions in 419 patients 
with axSpA the study identified 15 clusters. The 
depression-anxiety group was one of the most 
prevalent clusters, with patients in this group 
scoring higher on disease activity and lower on 
quality of life measures.36
Three systematic literature reviews and meta-
analyses on the prevalence of depression in AS 
and PsA are reported.31,37,38 The largest meta-
analysis included 19,263 patients with AS from 
33 studies conducted in Europe, Asia and South 
America. These studies measured depression 
using a variety of methods including self-report, 
validated questionnaires, clinical interviews, 
administrative and hospital records. In one meta-
analysis, the pooled prevalence of depression in 
AS was reported to be 29%.37 However, findings 
from this meta-analysis were largely driven by one 
large study from Taiwan comprising 11,701 
patients,39 which used the Elixhauser comorbidity 
index to record ICD-9 identified diagnoses of 
depression,40 rather than direct assessment of 
mood using a validated scale/interview. Reliance 
on clinical diagnosis can lack temporal validity, 
provides no information on current symptom 
severity, and may underestimate prevalence due 
to subthreshold and undiagnosed depression.
Although another meta-analysis comprised fewer 
studies, the assessment of depression was more 
robust due to the inclusion criteria that studies 
must use a validated diagnostic and screening cri-
teria for depression, with a defined threshold.31 It 
included 14 studies of AS and two studies of non-
radiographic axial SpA (nr-axSpA), totalling 
4753 participants across all studies. Participants 
were recruited mainly from hospital settings such 
as rheumatology clinics, assessing depression 
using the well-validated Hospital Anxiety and 
Depression Scale (HADS). In individual studies 
included in this meta-analysis, the prevalence of 
depression ranged from 11% to 64% depending 
on the criteria and threshold used.31 According to 
this meta-analysis, pooled prevalence of mild 
depressive symptoms in patients with AS, axSpA 
and nr-axSpA was 38%, and that for moderate/
severe depression (defined as HADS score ⩾11) 
was 15%.31 The prevalence of depression was sim-
ilar between AS, axSpA and nr-axSpA cohorts. 
Patients with depression had significantly worse 
SpA disease activity and greater SpA-related func-
tional impairment. Younger age was associated 
with higher prevalence of depression.30 It is 
unclear why age was inversely correlated with risk 
of depression; however, it can be speculated that 
earlier onset rheumatological disease may cause a 
greater psychological burden due to increased 
severity and perceived impact on activity/func-
tioning compared with healthy young peers. The 
majority of included studies recruited participants 
from hospital settings, which may result in higher 
SpA disease activity and functional impairment 
than primary care samples. This could contribute 
to a higher prevalence of depression in these 
cohorts. However, the authors state that there was 
no correlation between disease activity and depres-
sion prevalence estimates and suggest other con-
founders such as smoking and deprivation could 
account for the higher disease activity and func-
tional impairment in depressed groups.
There are relatively fewer studies of the preva-
lence of depression in patients with PsA. A recent 
meta-analysis on this topic included three studies 
that collected participants from hospital settings 
such as outpatient facilities, rheumatology and 
dermatology clinics across South America, 
Europe, Canada, and Asia-Pacific, including a 
total of 1141 patients with PsA.38 Prevalence of 
moderate depression, assessed by HADS or the 
patient health questionnaire-9 (PHQ-9) criteria, 
across these studies ranged from 9% to 22%, with 
a pooled prevalence of 15% [95% confidence 
interval (CI), 9–21%], which is similar to preva-
lence of moderate depression in AS. However, 
these studies did not report prevalence for mild 
mood disorders in PsA. There is evidence that 
depression and anxiety is greater in PsA com-
pared with psoriasis without arthritis, suggesting 
that risk for mood disorders could be associated 
with disease-related factors.41 Interestingly, 
depression has been reported to increase the risk 
of PsA in people with psoriasis. In a study using 
25-years of primary care medical records, 73,447 
patients with psoriasis were identified. Diagnosis 
of major depressive disorder (MDD) was reported 
to increase the risk of developing PsA by 37%, 
even when controlling for multiple covariates 
(hazard ratio 1.37; 95% CI, 1.05–1.80).42 In 
another longitudinal study of PsA, pain was asso-
ciated with subsequent development of depres-
sion and vice versa.43
With regards to incidence of depression in patients 
with AS and PsA, two recent systematic literature 
review and meta-analyses compared incidence of 
depression in these patient groups with that in 
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healthy populations.37,44 Comprising 5947 patients 
with AS from three studies conducted in Taiwan, 
Sweden and the United States (US), a pooled rate 
ratio (RR) for depression in AS was 1.51 (95% CI, 
1.28–1.79).37 This 51% increase in risk was calcu-
lated based on studies that report incidence rates 
within 1 year,45 10 years,46 and 13 years of develop-
ing AS.47 Smoking and lower education were 
reported to be associated with a higher risk of 
depression.48,49 The literature search for this review 
was carried out in 2018, therefore missing more 
recent studies. One large-scale nationwide study 
from South Korea based on 11,465 newly diag-
nosed cases of AS between 2010 and 2014 reported 
that, compared with age- and sex-matched con-
trols, there was a two-fold increased risk of incident 
depression in patients with AS, even after control-
ling for potential confounders and comorbidities 
(adjusted hazard ratio 2.21; 95% CI, 2.06–2.36).50 
Moreover, the cumulative incidence of depression 
grew over a 6-year period, suggesting that risk of 
depression increases over time in patients with 
AS.50 In this sample, female sex, lower socioeco-
nomic status, and the number of comorbidities 
were associated with a higher risk of developing 
depression.50 Similarly, a nationwide population-
based study from Taiwan examined the risk of 
depression in 2331 patients with AS during a 
median 6-year follow-up period. The study 
reported that following AS diagnosis patients had a 
three-fold increased risk of depression in the first 
year and two-fold increased risk after ⩾5 years.46
Regarding the incidence of depression in PsA, four 
studies were included in a meta-analysis.44 These 
studies comprised a total of 28,614 patients with 
PsA from the US, and assessed annual incidence 
following PsA diagnosis. The pooled incidence 
rate ratio for depression was reported to be 1.44 
(95% CI, 1.20–1.73), which was independent of 
PsA severity. The authors observed that, despite 
increased rates of depression, only 2.4–13.5% of 
patients with PsA were taking antidepressant med-
ication, suggesting that many PsA patients who 
have comorbid depression may not be receiving 
treatment for their depression. Although incidence 
of depression appears to be elevated in AS and 
PsA, incidence may be over-estimated in hospital-
based samples due to increased surveillance.
Common risk factors for depression in AS or 
PsA patients
Depression is a complex multifactorial disorder 
with contributions from both environmental and 
genetic factors. Female sex, exposure to stressful 
life events in childhood/adulthood, and socioeco-
nomic deprivation are some of the most exten-
sively replicated factors associated with 
depression.51–54 Examples of stressful life events 
reported to be associated with depression include 
bereavement, physical, emotional or sexual abuse, 
relationship breakdown, lack of employment or 
confiding relationship, and financial prob-
lems.52,53 At the physiological level, effects of life 
stressors are possibly mediated by activation of 
the hypothalamic-pituitary-adrenal (HPA) axis 
and low-grade systemic inflammation.55–58 
Stressful life events could be a useful marker for 
identifying those potentially at risk of depression 
in clinical settings. History of depression is also a 
significant risk factor for subsequent depression,59 
which could be another important risk indicator 
in clinical settings.
The association of stressful life events and depri-
vation with depression have also been replicated 
in patients with AS, axSpA, and psoriasis. For 
instance, stress and lower household income have 
been reported to double the risk of depression in 
axSpA.60 As mentioned in the previous section, 
lower socioeconomic status or educational 
achievement, smoking and number of comorbidi-
ties have been reported to be associated with risk 
of depression in large population studies of AS.48–50 
A number of comorbidities are common in 
patients with AS and PsA, including cardiovascu-
lar disease,61,62 malignancies,63,64 gastrointesti-
nal disorders,65,66 among others.64 Many of 
these increase the subsequent risk of depression, 
and/or vice versa.67–69 Moreover, multimorbidity 
increases risk of depression dependent on the 
number of physical morbidities.70 Although it is 
difficult to ascertain whether depression is a result 
of multimorbidity, AS, or PsA, it is likely multi-
morbidity increases psychological and immune 
system stress, and may present potential path-
ways through which depression and multimorbid-
ity may be linked. In contrast, results regarding 
association between depression and sex in patients 
with AS is somewhat mixed; with studies report-
ing higher risk in females,50 males,71 or no differ-
ence.47,60 Therefore, it is possible that the risk of 
depression in AS could be relatively similar 
between the sexes. Although there is limited lit-
erature on the link between stress, socioeconomic 
status and PsA, low socioeconomic status has 
been found to increase the risk of depression 
[odds ratio (OR) 1.17, 95% CI 1.08 1.26], anxi-
ety (OR 1.11, 95% CI 1.01 1.23) and mixed 
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anxiety/depression (OR 1.32, 95% CI 1.21 1.45) 
in psoriasis when compared with healthy controls. 
Furthermore, low socioeconomic status increased 
the cumulative probability of anxiety and depres-
sion between the ages of 40 and 60 years.72
Potential mechanisms of depression in  
AS or PsA patients
Role of disease-related factors
Disease severity, poor quality of life and particu-
lar symptoms of AS such as fatigue and sleep dis-
turbance have been reported to be associated with 
depression in patients with AS. In one study, for 
every unit increase in the Bath AS Disease Activity 
Index (BASDAI; scale 0–10) the risk of depres-
sion in patients with AS increased by 30%.60 In 
another study, although both disease activity 
(BASDAI) and AS quality of life scores were 
moderately correlated with depression (r = 0.50 
and 0.60, respectively), multivariable linear 
regression showed that only poor quality of life 
was independently associated with depression 
after taking into account both scores.73 However, 
disease activity could still be an important risk 
factor, given the magnitude of its correlation with 
depression (r = 0.50). Although it is apparent 
there is a relationship between disease activity, 
quality of life and depression, cross-sectional data 
such as these are unable to ascertain the direction 
of association (i.e. whether depression is a cause 
or consequence of poor quality of life, disease 
activity). Longitudinal studies are required to 
address this issue.
Fatigue is a common symptom in AS, with two 
studies reporting a correlation with depression 
severity (r ⩽ 0.55).74,75 Considering these two 
studies were based on relatively small samples 
(80 and 65 cases of AS), the correlation estimates 
are relatively large and may indicate a significant 
role of fatigue in depression in patients with AS. 
Similarly, sleep quality appears to be related to 
depressive symptoms. In samples of 318 and 80 
patients with AS, Spearman’s correlation 
between sleep problems and depression was 
reported to be 0.47 and 0.31, respectively.76,77 
Despite moderate correlations between disease 
related factors and depression, it is difficult to 
ascertain from cross-sectional data whether 
fatigue, sleep problems, quality of life and/or dis-
ease activity are a cause or consequence of 
depression. This is because depression could 
cause or exacerbate these factors of AS, or both 
depression and AS may share pathophysiologic 
mechanisms that contribute to the development 
of these symptoms.
Similarly, disease-related factors can also lead 
to depression in PsA. Although directionality 
has not been investigated, PsA disease activity 
is greater in patients with depression and/or 
anxiety.78 Similar to AS, sleep and fatigue have 
been reported to be associated with poor qual-
ity of life and risk of depression in patients with 
PsA.30,79,80 Other PsA symptoms may further 
affect depression risk. For instance, psoriasis 
has been shown to impair body image.81 Using 
hierarchical multiple regression, psoriasis sever-
ity and a younger age of onset has been associ-
ated with anxiety, while negative body image 
mediated the relationship between the severity 
of psoriasis and depression.82 Pain could also 
be a risk factor for depression. In a longitudinal 
study pain was associated with subsequent 
development of depression and vice versa in 
patients with PsA.43
Inflammation as potential shared mechanism 
for both depression and SpA
Several lines of evidence suggest the potential role 
of systemic inflammation, a hallmark of SpA and 
other rheumatological conditions, in the patho-
genesis of depression. Autoimmune disease and 
severe infection are associated with increased risk 
for subsequent depression, with all 30 autoim-
mune disorders assessed (including AS and pso-
riasis) increasing risk.58 Interferon treatment, a 
potent inducer of innate immune response, leads 
to development of depression in up to 40% of 
patients with hepatitis C virus.83 A meta-analysis 
of cross-sectional studies have consistently 
reported increased concentrations of C-reactive 
protein (CRP) and inflammatory cytokines, such 
as IL-6 and TNF-α in the peripheral blood and 
cerebrospinal fluid (CSF) of patients with acute 
depression compared with healthy controls.84–87 
Population-based longitudinal studies have 
reported that elevated circulating IL-6 and CRP 
levels in childhood are associated with the subse-
quent development or persistence of depressive 
symptoms in adulthood,88–90 suggesting that 
inflammation could be a cause, rather than a con-
sequence of depression. Mendelian randomisa-
tion studies, which use genetic variants regulating 
levels/activity of a biomarker as proxies to address 
the issue of confounding,91 suggest that IL-6 and 
CRP could be potentially causally related to 
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depression, rather than these associations being 
fully attributable to confounding by lifestyle, 
stress or other factors.92,93
Inflammation appears to be clinically relevant as it 
is associated with poor antidepressant response.94,95 
Evidence from clinical trials also supports a role 
of inflammation in depression, with recent stud-
ies pointing to key roles for inflammatory 
cytokines such as IL-6 and TNF-α. In cohorts 
that include depressed but otherwise healthy par-
ticipants and participants with depression and 
comorbid osteoarthritis, non-steroidal anti-
inflammatory drugs (NSAIDs) given as adjuncts 
to antidepressants are associated with greater 
symptomatic improvements compared with anti-
depressants alone in randomised controlled trials 
(RCTs).96 More recently, meta-analyses of sec-
ondary outcome data from RCTs of cytokine 
antagonists, including anti-TNF, anti-IL-6/
IL-6R, anti-IL-12/23, anti-IL-4/13 and anti-
IL-17 drugs in patients with rheumatoid arthritis, 
inflammatory bowel disease and other chronic 
inflammatory physical illness have reported that 
these drugs improve depressive symptoms inde-
pendently of improvements in physical illness.97,98 
Based on seven placebo-controlled studies, there 
was a moderate effect size (0.40; 95% CI 0.22–
0.59) of anti-cytokine treatment on depressive 
symptoms, with the majority of studies investigat-
ing anti-IL-6 and anti-TNF treatments.97 In a 
subsequent review, similar effects were observed, 
demonstrating the largest antidepressant effects 
in anti-IL-6 and anti-IL12/23 drug classes. After 
controlling for physical health outcomes, a trend 
remained for anti-IL-6, while anti-IL-12/23 
effects remained significant, with both showing 
only marginal attenuation.98
Currently a number of RCTs are testing the 
effects of cytokine and/or cytokine receptor antag-
onists in patients with depression. However, 
identifying patients most likely to benefit from 
immunotherapy is likely to be key for the success 
of future RCTs, as inflammation is unlikely to be 
relevant for all patients with depression.99 A RCT 
of infliximab for treatment resistant depression 
demonstrated treatment response to be associ-
ated with higher baseline CRP levels.100 A proof-
of-concept double blind RCT of the anti-IL-6R 
mAb tocilizumab in patients with depression is 
underway, with subjects selected based upon evi-
dence of inflammation and inflammation-related 
symptoms.101
Turning to data from patients with AS, the mood 
improving effects of infliximab is consistent with a 
potentially shared role of inflammation in patho-
genesis of depression, AS and other chronic 
inflammatory physical illness.102 Sickness behav-
iour, a response to inflammation in autoimmune 
disease or infection, is characterised by fatigue, 
sleep problems, anhedonia, reduced appetite, 
concentration and motivation, which are also typi-
cal symptoms of depression.103 The depression 
syndrome consists of heterogeneous symptoms. 
Data from population-based studies suggest that 
elevated levels of circulating IL-6 and CRP are 
associated with particular symptoms of depres-
sion, such as fatigue, sleep and appetite distur-
bance, which are akin to sickness behaviour.104,105
Specific biologic pathways involved in the 
pathologies of depression and SpA show some 
concurrence. Whilst the pathogenesis of AS, 
PsA and depression is yet to be fully under-
stood, recent evidence highlights the IL-17/23 
pathway as one of the most important cytokine 
pathways to contribute to AS and PsA.6,106–108 
Elevated IL-23 impairs T helper cells, which 
contributes to the overexpression of IL-17, 
IL-22, IL-1, IL-6 and TNF. Interestingly, there 
is evidence of impaired T helper function in 
depression.109 IL-6, IL-1β, TNF-α and CRP are 
also among inflammatory markers shown con-
sistently to be elevated in patients with depres-
sion.97,110,111 Nuclear factor (NF)-κB is another 
marker that has been implicated in both AS and 
depression,112,113 as are inflammasomes.114–116 
Production of these inflammatory proteins may 
be activated by psychological stress through the 
hypothalamic pituitary adrenal (HPA) axis. The 
HPA axis stimulates the release of glucocorti-
coids and catecholamines, initiating inflammas-
ome assembly,109 which in turn leads to the 
production of IL-1β and other pro-inflamma-
tory cytokines such as IL-18.117
To date, the medical literature has considered the 
brain as an immune-privileged site, shielded 
behind the blood-brain barrier. However, current 
evidence demonstrates a number of pathways 
through which peripheral inflammation can com-
municate with the brain. While the exact neuro-
chemical basis of inflammation-induced depression 
is still being elucidated, current evidence suggests 
that inflammatory cytokines can influence mood, 
cognition and behaviour by: (i) decreasing synap-
tic availability of serotonin by breaking down 
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tryptophan along the kynurenine pathway, and by 
increasing presynaptic reuptake of serotonin; (ii) 
increasing oxidative stress due to production of 
reactive oxygen and nitrogen species; (iii) increas-
ing synaptic glutamate leading to excitotoxicity; 
and (iv) decreasing neurotrophic support and 
hippocampal neurogenesis. See Figure 1, and 
reviews by Dantzer et al. and Miller and Raison 
for a more detailed narrative.23,109
Shared genetic basis for neuropsychiatric and 
immune disorders
While no data is currently available on a shared 
genetic basis for depression and AS specifically, 
emerging evidence indicates a potential shared 
genetic basis for a number of neuropsychiatric 
and immunological disorders.118 One study inves-
tigating genetic variants associated with psychiat-
ric illnesses (schizophrenia, bipolar disorder, 
major depressive disorder, and autism spectrum 
disorder) and autoimmune diseases (Crohn’s dis-
ease, ulcerative colitis, multiple sclerosis, psoria-
sis, RA, SLE and insulin-dependent diabetes 
mellitus) reported evidence for genetic pleiotropy 
in 24 out of 35 psychiatric-immune disorder 
pairs.118 The strongest pleiotropy was observed 
for schizophrenia-rheumatoid arthritis with MHC 
region included in the analysis, and schizophre-
nia-Crohn’s disease with MHC region 
excluded.118 Using linkage disequilibrium score 
regression (LDSC) analysis of available genome-
wide association studies (GWAS) data, another 
study reported significant genetic correlations 
Figure 1. Pathways through which peripheral inflammation can communicate with the brain and influence 
mood, cognition and behaviour. Cellular route refers to the trafficking and attraction of immune cells to the 
brain vasculature and parenchyma, such as through the meningeal lymphatic system. Neural pathway involves 
activation of the vagus nerve by peripheral cytokines, with the signal reaching brain nuclei by retrograde 
axonal transport. Humoral pathway involves production of cytokines by macrophage-like cells in the 
circumventricular organs, which can enter the brain by volume diffusion. Figure reproduced from Miller and 
Raison with permission from Springer Nature.109
DAMPs, damage-associated molecular patterns; MAMPs, microbe-associated molecular patterns.
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between immune-related disorders and several 
psychiatric disorders including depression.119 RA 
was the only rheumatologic condition included in 
this study, which showed evidence for genetic 
correlations with bipolar disorder, obsessive com-
pulsive disorder, attention deficit-hyperactivity 
disorder and smoking behaviour. With further 
GWAS using larger samples, future studies may 
shed light on potential shared genetic basis for 
spondyloarthritis, depression and other psychiat-
ric disorders.
Management of depression in SpA
Depression is a treatable condition with about 
two-thirds of patients responding to first-line 
antidepressant treatment.22 Depression is associ-
ated with poor treatment adherence, poor 
response to biologics, and higher self-reported 
disease severity in patients with arthritis.33,34 
Therefore, it is imperative for clinicians to actively 
assess and treat depression in AS and other rheu-
matologic conditions rather than seeing depres-
sion as an inevitable by-product of arthritis, pain 
or poor quality of life. Based on prevalence stud-
ies discussed earlier, it is likely that about 40% of 
patients with AS will have some degree of depres-
sive symptoms while moderate to severe depres-
sion is likely to be present in about 15% of patients 
with AS and PsA.31,38 Therefore, routine assess-
ment of depression in rheumatology clinics is 
necessary to identify these patients, and tailor 
management strategy accordingly based on 
depression severity and potential risk.
The UK National Institute for Health and Care 
Excellence (NICE) recommends depression is 
assessed in patients with RA on an annual basis. 
However, it is noteworthy that, with the excep-
tion of the National Axial Spondyloarthritis 
Society (NASS), existing international guidelines 
for AS do not mention depression, despite this 
being a common problem in these patients. The 
NASS recommends that patients with AS see 
their primary care physician for advice if con-
cerned about their mental wellbeing.
Assessment of depression and associated risk
The NICE guidelines on the recognition and 
management of depression in adults with a 
chronic physical health problem provides clini-
cians not trained in psychiatry with useful sugges-
tions for assessment of depressive symptoms, 
severity and potential risks (see Textbox 1 for 
summary).120
The NICE guidelines recommend using a vali-
dated tool to assess depression. A number of vali-
dated questionnaires for assessing depression are 
available, such as the PHQ-9, Beck Depression 
Inventory-II (BDI-II) and HADS.121 The PHQ-9 
may be particularly useful in rheumatology clin-
ics, as it is a validated, brief, self-report tool widely 
used to assess depression in clinical and commu-
nity samples including in UK primary care.122 
Furthermore, it has been reported that people 
with arthritis respond to items on the PHQ-9 sim-
ilarly to those without arthritis, despite the inclu-
sion of somatic items in this scale.123 This 
nine-item questionnaire assesses depressive 
symptoms occurring in the past 2 weeks. Each 
item is rated as not present (0), present several 
days (1), more than half the days (2), and nearly 
every day (3), giving a total depression symptom 
score of 0–27. Using established thresholds, the 
score can provide useful categories of depression: 
no depression (score 0–4); mild depression (5–9); 
moderate depression (10–14); moderately severe 
depression (15–19); and severe depression (20–
27). A PHQ-9 score ⩾10 has a sensitivity of 88% 
and a specificity of 88% for major depression.122 
The BDI-II could be also useful, as similar to 
PHQ-9, it focusses mainly on cognitive and psy-
chological aspects of depression, unlike the 
Hamilton Depression Rating Scale (HAM-D), 
which includes a number of physical symptoms, 
making assessment of depression in people with 
physical illness somewhat tricky. HADS is also 
used commonly as it measures both depression 
and anxiety, but it lacks any questions covering 
suicidal ideation, which is needed to inform risk 
assessment, an important part of assessment of 
depression according to the NICE guidelines.
Regarding assessment of suicide risk, it is impor-
tant for clinicians to know that asking about sui-
cide and related behaviours does not increase the 
risk of suicide.124 Suicidal ideation is common in 
the general population and in people with depres-
sion. According to the British National Psychiatric 
Morbidity Survey, a general population-based 
survey conducted in 2000, nearly one in six indi-
viduals had had death wishes or considered sui-
cide, while 4.4% of the study population had 
attempted suicide at some time.125 Prevalence of 
suicidal thoughts in individuals with depression is 
higher, ranging up to over 60%.126,127 Although 
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suicidal ideation is relatively common, certain 
features may indicate higher risk of suicide 
attempt, such as having a plan, past suicide 
attempt, recent onset, and time spent thinking 
about suicide.128 PHQ-9 and some of the other 
questionnaires mentioned above can be a good 
starting point for identifying suicidal ideation, fol-
lowed by further questioning including assess-
ment of aggravating and protective factors, may 
help clinicians to gauge the need for referral to 
specialist services.
Treatment considerations
Assessing severity and risk can inform a stepwise 
approach to treatment of depression taking into 
account individual patient preference. According 
to the NICE guidelines on recognition and man-
agement of depression in adults,129 antidepres-
sants are not recommended as a first-line 
treatment in recent onset, mild depression. 
Rather, active monitoring, individual guided self-
help, cognitive behavioural therapy (CBT) or 
exercise are preferred. According to recommen-
dations from the Canadian Dermatology-
Rheumatology Comorbidity Initiative expert 
group, optimising treatment for rheumatologic 
condition may also be helpful for depression, as 
better disease control has been reported to reduce 
symptoms of depression in patients with RA, 
PsA, and psoriasis.130 Furthermore, a recent sys-
tematic review and meta-analysis has reported 
that anti-cytokine drugs improve depressive 
symptoms in patients with chronic inflammatory 
physical illness, such as RA and psoriasis, inde-
pendently of improving physical illness.96
According to the NICE guidelines, antidepres-
sants are recommended for the treatment of mod-
erate or severe depression with SSRIs being 
Textbox 1. Summary of the NICE guidelines for the recognition and management of depression in adults with 
a chronic physical health problem. Clinical guideline (CG91), October 2009 (Section 1.3).
Identification and recognition (Section 1.3.1)
1. Be alert to depression, especially those at greater risk. Consider two questions:
○ during the last month, have you often been bothered by feeling down, depressed or hopeless?
○ during the last month, have you often been bothered by having little interest or pleasure in doing 
things?
2. If the answer to either is yes and the clinician is trained, three further questions below should be asked. 
If not trained, a referral should be made to the appropriate specialist and/or general practitioner.
○ during the last month, have you often been bothered by feelings of worthlessness?
○ during the last month, have you often been bothered by poor concentration?
○ during the last month, have you often been bothered by thoughts of death?
A practitioner may also want to review patients mental state, associated functional, interpersonal 
and social difficulties; consider the role of both the chronic physical health problem and prescribed 
medication in the development or maintenance of depression; and/or ascertain that the optimal 
treatment for the physical health problem is being provided, seeking specialist advice if necessary.
3. When depression is suspected, consider using a validated measure (for symptoms, functions and/
or disability) to inform and evaluate treatment (alternatives provided and suggested for those with 
communication difficulties).
Risk assessment and monitoring (Section 1.3.2)
1. If a patient with depression and a chronic physical health problem presents considerable immediate 
risk to themselves or others, refer them urgently to specialist mental health services.
2. Advise patients with depression and a chronic physical health problem of the potential for increased 
agitation, anxiety and suicidal ideation in the initial stages of treatment for depression. Patient, family, 
or carer should be vigilant for mood changes, negativity and hopelessness, and suicidal ideation, and to 
contact their practitioner if concerned.
○ ensure that the patient knows how to seek help promptly
○ review treatment if patient develops marked and/or prolonged agitation.
3. If a patient with depression and a chronic physical health problem is assessed to be at risk of suicide:
○ take into account toxicity in overdose if an antidepressant is prescribed or the patient is taking other 
medication; if necessary, limit the amount of drug(s) available
○ consider increasing the level of support, such as more frequent direct or telephone contacts
○ consider referral to specialist mental health services.
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recommended as the first-line treatment, pre-
scribed at a dose likely to be effective after titra-
tion, if necessary.129 Important points to discuss 
with all patients include choice of drug, utility/
availability of non-pharmacological options (e.g. 
CBT), likely outcome (i.e. gradual relief of symp-
toms over several weeks), need to continue treat-
ment after resolution of symptoms (e.g. at least 
6–9 months after first episode of depression), and 
risk and nature of discontinuation symptoms.
Although SSRIs are recommended as first-line, use 
of these drugs in patients with AS and other rheu-
matologic conditions may be problematic due to 
increased risk of peptic ulcer and gastrointestinal 
(GI), uterine, cerebral and perioperative bleed-
ing. A meta-analysis of 42 observational studies 
reported a significant association between SSRI 
use and the risk of bleeding (OR = 1.41; 95% CI, 
1.27–1.57).131 It is thought that SSRIs deplete 
platelet serotonin leading to reduced ability to 
form clots and subsequent increase in the risk of 
bleeding.131 Risk factors for bleeding with SSRIs 
include older age (particularly >65 years), alco-
hol misuse, coronary artery disease, hypertension, 
history of GI bleeding, stroke, peptic ulcer, liver 
disease and medication usage predisposing to 
bleeding.132 Therefore, caution should be exer-
cised when prescribing SSRIs for patients taking 
NSAIDs, aspirin, anticoagulants or corticoster-
oids, and for patients with a history of gout, 
asthma, lupus, psoriasis, etc.132
The Maudsley prescribing guidelines in psychia-
try, based on limited evidence, suggest that risk 
of bleeding may be lower with non-SSRI antide-
pressants that have weak or no effect on seroto-
nin reuptake inhibition, such as mirtazapine, 
lofepramine and nortriptyline, as opposed to highly 
potent SSRIs such as fluoxetine or sertraline.132 
The Maudsley guidelines also suggest that if SSRI 
use cannot be avoided, to monitor patients closely 
and prescribe gastro-protective proton pump 
inhibitors.132 Further on drug interaction, SSRIs 
may increase risk of serotonin syndrome when pre-
scribed with other serotonergic drugs (e.g. trama-
dol) and electrolyte disturbance on their own and 
together with diuretics.132 Toxicity of medications 
in overdose may need to be considered especially 
for patients deemed high risk of overdose/suicide.
When to consider psychiatric referral
For community-based patients, the NICE guide-
lines recommend referral to their primary care 
physician for further assessment when depression 
is suspected, if the clinician is not trained/compe-
tent to perform this assessment (see Textbox 1). 
Patients should be informed if referrals to spe-
cialist mental health services are made. While for 
the majority of patients a referral to a general 
practitioner (GP) is likely to be the appropriate 
route, specialist psychiatric referral should be 
considered for more complex or high-risk 
patients. Such scenarios may include treatment 
resistance (i.e. failure to respond to two or more 
antidepressants), bipolar depression (antidepres-
sant may induce mania) or multi-morbidity (e.g. 
comorbid complex/severe physical illness or 
other psychiatric disorders such as schizophrenia, 
anxiety disorder, personality disorder, substance 
use). In such scenarios, specialist psychiatric 
input could help to inform specific treatment con-
siderations. Risk of suicide may also require more 
immediate intervention or more specialised 
assessment and care.
Pathways to specialist mental health care differ 
widely depending on area or country. For patients 
in the community, GPs in the UK are best placed 
to refer patients to appropriate mental health 
services as they are aware of local service provi-
sion and care pathway arrangements. In hospital 
settings, referrals to specialist liaison psychiatry 
services would be most appropriate. Liaison psy-
chiatry provides specialist assessment and advice 
for management of patients across the range of 
psychiatric conditions, including depression. 
Naturally, this enables collaboration between 
specialists in rheumatology and psychiatry, and 
the best course of treatment can be mutually 
determined.
Conclusion
Depression is a major neuropsychiatric disorder, 
which is common in patients with rheumatologi-
cal conditions including spondyloarthritis and is 
associated with poor treatment response and qual-
ity of life (see Textbox 2 for summary of key con-
clusions). Based on meta-analysis, about 40% of 
patients with AS show some depressive symptoms 
while moderate/severe depression is present in 
about 15% of AS and PsA patients. Longitudinal 
studies indicate that the risk of depression in 
patients with AS or PsA increases over time. Risk 
factors for depression in the general population 
include socioeconomic deprivation and stressful 
life events such as abuse, relationship breakdown, 
lack of employment or confiding relationship, and 
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financial problems. In AS and PsA, there are addi-
tional disease-related factors that may increase the 
risk of depression, such as disease activity, quality 
of life, sleep and fatigue. Furthermore, accumulat-
ing evidence suggests a potential causal role for 
inflammation in depression, which could be a 
shared mechanism for these conditions.
Given the strong associations of depression with 
poor treatment response, disease severity and 
quality of life in patients with rheumatologic con-
ditions, it is crucial for clinicians in rheumatology 
services to actively assess and treat depression. 
Optimal management of depression in AS would 
be aided by routine assessment of depression 
using validated tools such as the PHQ-9 ques-
tionnaire. While optimising disease control and 
non-pharmacological interventions such as 
guided self-help, exercise or psychotherapy is 
likely to be helpful for mild depression, treatment 
with antidepressant drugs is recommended for 
those with moderate/severe depression. However, 
choice of antidepressant requires careful consid-
eration because of potential risk of adverse effects, 
such as bleeding, from concurrent use of high 
potency SSRIs and anti-inflammatory drugs.
Similar to other common conditions such as 
hypertension, it is likely that care for the majority 
of patients with comorbid depression and AS/
other rheumatologic conditions will remain under 
GPs and rheumatology services. Specialist psy-
chiatric referral should be considered for more 
complex or high-risk patients, such as patients 
with multimorbidity, antidepressant resistance, 
substance misuse or suicide risk. In hospital set-
tings, this would involve collaborative working 
between rheumatologists and liaison psychiatrists 
to ensure the best possible outcome for patients.
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Textbox 2. Summary of key conclusions.
• Better recognition and treatment of depression in rheumatology clinics is necessary as depression is 
associated with poor clinical outcomes in rheumatology patients.
• Patients with SpA have increased risk of depression, with mild depressive symptoms being present in 
about 40% and moderate/severe depression in about 15%.
• SpA-related factors most strongly associated with depression are disease activity, poor quality of life, 
fatigue, and sleep disturbance.
• Emerging evidence indicates that inflammation, particularly proinflammatory cytokines, could be a 
potential shared mechanism for depression and SpA.
• Optimal management of depression in SpA would be aided by routine assessment of depression using 
validated tools such as the PHQ-9 questionnaire.
• Optimising disease control and non-pharmacological interventions such as guided self-help, exercise or 
psychotherapy is likely to be helpful for mild depression, while antidepressants are recommended for 
those with moderate/severe depression.
• Choice of antidepressant requires careful consideration because of potential risk of adverse effects, 
such as bleeding, from concurrent use of high potency SSRIs and anti-inflammatory drugs.
• Referral to specialist mental health services should be considered for more complex or high-risk patients, 
such as patients with multimorbidity, antidepressant resistance, substance misuse or suicide risk.
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